SEATTLE, July 27, 2021, (MEDGADGET) — Global Stomach Cancer Drugs Market – Insights
Stomach cancer is a type of cancer that develops when abnormal cells form a mass in the stomach. Feeling bloated after eating, severe indigestion, persistent vomiting, unintentional weight loss, severe heartburn, persistent nausea, fatigue and stomach pain are all symptoms of stomach cancer. Targeted drug therapy, chemotherapy, and immunotherapy are some of the stomach cancer treatments available. Combinations of stomach cancer drugs are also used to boost their efficacy in the fight against stomach cancer. TPF, for example, is a drug cocktail that includes Docetaxel (Taxotere), Cisplatin (Platinol), and Fluorouracil, and is used to destroy cancer cells in a variety of ways.
The global demand for stomach cancer drugs was estimated at US$ 4.0 million in 2017 and is projected to develop at a CAGR of 5.4 percent from 2018 to 2026.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2667
The stomach cancer drugs market is expected to expand due to an increase in FDA approvals of biosimilars for the treatment of stomach cancer:
Because of the growing number of FDA approvals for biosimilars, the market for stomach cancer treatments is likely to grow. Biosimilars have been in high demand in the last five years due to their lower cost than biologics for the treatment of stomach cancer. For example, in 2017, Biocon Ltd. obtained FDA approval for Ogivri (trastuzumab) for the treatment of stomach cancer or gastro-esophageal junction adenocarcinoma in collaboration with Mylan N.V. Ogivri is the first biosimilar of Herceptin to be authorized by the FDA, as well as the first biosimilar from Mylan and Biocon’s joint portfolio. TRAZIMERA (trastuzumab), a biosimilar of Herceptin (trastuzumab), was approved by the US Food and Drug Administration (FDA) in March 2019 for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Furthermore, favorable reimbursement policies for stomach cancer drugs are a significant factor in the market’s development. There are government and private healthcare programs that cover the costs of stomach cancer medications, which increase drug adoption as a result of these policies. According to Bristol-Meyer Squibb, Medicare Part B would cover 80% of the cost of Opdivo, while the remaining 20% is the patient’s liability. Opdivo is currently undergoing a phase 3 clinical trial for the treatment of stomach cancer.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Flat Instant discount of US$ 2000
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2667
Restraints:
The severe side effects caused by the drugs are one of the main restraints of the stomach cancer drugs industry. In patients receiving treatment for stomach cancer, side effects like loss of appetite and weight loss, blood clots (Deep Vein Thrombosis), diarrhea, hand-foot syndrome, nausea and vomiting, heart damage, fatigue, low blood cell counts, and hair loss in patients is observed often. Chemotherapy drugs including doxorubicin and epirubicin can cause irreversible heart damage if used for a long time or in large doses, according to a 2017 study by the American Cancer Society (ACS) on side effects of stomach cancer. Other medications, such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel, can damage nerves outside the brain and spinal cord, according to the same source.
Regional Insights:
On the basis of region, the global stomach cancer drugs market is segmented into Latin America, Europe, Asia Pacific, North America, Africa, and Middle East. North America is projected to maintain a dominant role in the global stomach cancer drugs market, owing to an increase in the number of clinical trials for stomach cancer drug production. In 2016, Bristol-Myers Squibb, for example, began a clinical trial to assess a combination of therapies for stomach cancer. A trial to see which treatment is more successful in treating patients with advanced stomach cancer: Nivolumab in combination with other therapies or Nivolumab in combination with Ipilimumab. The thesis entered phase 2 in February 2019 and is expected to be completed in 2021.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/stomach-cancer-drugs-market-to-surpass-us-66-billion-by-2026-1415
Due to an increase in the launch of biosimilars for treating stomach cancer, Asia Pacific is expected to see a rapid growth in the stomach cancer drugs industry. Dr. Reddy’s Laboratories, for example, introduced Hervycta trastuzumab (Herceptin biosimilar) in India in 2018. The drug will be marketed under the name Hervycta and will be used to treat metastatic gastric cancer, according to Dr. Reddy’s Laboratories, which have created the biosimilar. Tratuzumab, a biosimilar, is Dr. Reddy’s fourth biosimilar to be commercialized in India and other emerging markets.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Distribution Channel Analysis
- Pipeline Analysis
- Regulatory Landscape
- Reimbursement Scenario
- Merger and Acquisition
- Epidemiology Analysis
- Market Dynamics
- Global Stomach Cancer Drugs Market, By Therapy Type, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Nucleoside Metabolic Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- VEGF Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- HER2 Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Car T Cell Therapy Trastuzumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Trastuzumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Introduction
- Global Stomach Cancer Drugs Market, By Application, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Adenocarcinomas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Gastrointestinal Stromal Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Carcinoid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Introduction
- Global Stomach Cancer Drugs Market, By Distribution Channel, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
- Introduction
- Global Stomach Cancer Drugs Market, By Region, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2026
- Regional Trends
- North America
- Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
- Market Size and Forecast, Distribution Channel, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Company Profiles
- Analyst Views
- Section
-
- References
- Research Methodology
- About Us and Sales Contact
Have a Look at Related Research Insights:
Esophageal Cancer Drugs Market To Surpass US$ 1,547.8 Million By 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837